<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lachance G</submitter><funding>Canadian Cancer Society Research Institute (Soci&amp;amp;#x00E9;t&amp;amp;#x00E9; Canadienne du Cancer)</funding><funding>Gouvernement du Canada | Canadian Institutes of Health Research</funding><funding>Diabetes Canada</funding><funding>Canadian Cancer Society Research Institute</funding><funding>W. Garfield Weston Foundation</funding><pagination>3431</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11039720</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(1)</volume><pubmed_abstract>The gut microbiota modulates response to hormonal treatments in prostate cancer (PCa) patients, but whether it influences PCa progression remains unknown. Here, we show a reduction in fecal microbiota alpha-diversity correlating with increase tumour burden in two distinct groups of hormonotherapy naïve PCa patients and three murine PCa models. Fecal microbiota transplantation (FMT) from patients with high PCa volume is sufficient to stimulate the growth of mouse PCa revealing the existence of a gut microbiome-cancer crosstalk. Analysis of gut microbial-related pathways in mice with aggressive PCa identifies three enzymes responsible for the metabolism of long-chain fatty acids (LCFA). Supplementation with LCFA omega-3 MAG-EPA is sufficient to reduce PCa growth in mice and cancer up-grading</pubmed_abstract><journal>Nature communications</journal><pubmed_title>The gut microbiome-prostate cancer crosstalk is modulated by dietary polyunsaturated long-chain fatty acids.</pubmed_title><pmcid>PMC11039720</pmcid><funding_grant_id>400345</funding_grant_id><pubmed_authors>Bouslama S</pubmed_authors><pubmed_authors>Hallal T</pubmed_authors><pubmed_authors>Feldiorean A</pubmed_authors><pubmed_authors>Ellis L</pubmed_authors><pubmed_authors>Julien IB</pubmed_authors><pubmed_authors>Lachance G</pubmed_authors><pubmed_authors>Piccirillo CA</pubmed_authors><pubmed_authors>Robitaille K</pubmed_authors><pubmed_authors>Boufaied N</pubmed_authors><pubmed_authors>Bergeron A</pubmed_authors><pubmed_authors>Varin TV</pubmed_authors><pubmed_authors>Gaignier F</pubmed_authors><pubmed_authors>Laaraj J</pubmed_authors><pubmed_authors>Raymond F</pubmed_authors><pubmed_authors>Pelletier JF</pubmed_authors><pubmed_authors>Derome N</pubmed_authors><pubmed_authors>Fradet Y</pubmed_authors><pubmed_authors>Labbe DP</pubmed_authors><pubmed_authors>Gevariya N</pubmed_authors><pubmed_authors>Fradet V</pubmed_authors><pubmed_authors>Xu HW</pubmed_authors><pubmed_authors>Marette A</pubmed_authors></additional><is_claimable>false</is_claimable><name>The gut microbiome-prostate cancer crosstalk is modulated by dietary polyunsaturated long-chain fatty acids.</name><description>The gut microbiota modulates response to hormonal treatments in prostate cancer (PCa) patients, but whether it influences PCa progression remains unknown. Here, we show a reduction in fecal microbiota alpha-diversity correlating with increase tumour burden in two distinct groups of hormonotherapy naïve PCa patients and three murine PCa models. Fecal microbiota transplantation (FMT) from patients with high PCa volume is sufficient to stimulate the growth of mouse PCa revealing the existence of a gut microbiome-cancer crosstalk. Analysis of gut microbial-related pathways in mice with aggressive PCa identifies three enzymes responsible for the metabolism of long-chain fatty acids (LCFA). Supplementation with LCFA omega-3 MAG-EPA is sufficient to reduce PCa growth in mice and cancer up-grading</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Apr</publication><modification>2026-06-02T01:42:56.869Z</modification><creation>2025-04-06T03:15:32.972Z</creation></dates><accession>S-EPMC11039720</accession><cross_references><pubmed>38654015</pubmed><doi>10.1038/s41467-024-45332-w</doi></cross_references></HashMap>